Elaris FlexCo, an Austrian biotechnology company developing vaccines against serious bacterial infections, announced on Wednesday that it has signed a licensing agreement with French vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) for technology related to Valneva's Clostridioides difficile vaccine candidate, VLA84.
Under the agreement, Elaris obtains an exclusive global licence to Valneva's antigen technology targeting Clostridioides difficile. Building on this technology, Elaris plans to advance a next-generation vaccine program incorporating additional proprietary components designed to broaden protective immune responses.
This agreement strengthens Elaris' intellectual property position and supports advancement of its lead vaccine programme. Elaris plans to advance the programme through IND-enabling development with the goal of initiating clinical studies around 2027.
4basebio introduces enzymatic ssDNA platform for gene editing applications
hVIVO secures Phase III human challenge trial contract with ILiAD Biotechnologies
Sanofi's Nuvaxovid demonstrates superior tolerability to Moderna's mNEXSPIKE in phase 4 study
hVIVO signs influenza human challenge trial agreement with Traws Pharma
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
GC Biopharma secures first Latin American approval for BARYCELA Inj.
Clover Biopharmaceuticals reports positive US Phase I data for RSV re-vaccination in older adults
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform